Literature DB >> 25999444

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

Lisa Pieri1, Alessandro Pancrazzi1, Annalisa Pacilli1, Claudia Rabuzzi1, Giada Rotunno1, Tiziana Fanelli1, Paola Guglielmelli1, Rajmonda Fjerza1, Chiara Paoli1, Srdan Verstovsek2, Alessandro M Vannucchi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25999444     DOI： 10.1182/blood-2015-01-624536

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

Review 1.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 2.  From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

Review 3.  Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.

Authors:  H Joachim Deeg; Christopher Bredeson; Stephanie Farnia; Karen Ballen; Vikas Gupta; Ruben A Mesa; Uday Popat; Parameswaran Hari; Wael Saber; Matthew Seftel; Roni Tamari; Effie W Petersdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-11       Impact factor: 5.742

Review 4.  Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Authors:  Elisa Rumi; Mario Cazzola
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

Review 5.  A rare CALR variant mutation and a review of CALR in essential thrombocythemia.

Authors:  Robert Diep; Ara Metjian
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

6.  Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis.

Authors:  Lucia Masarova; Wei Wang; Kate J Newberry; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2016-06-20       Impact factor: 25.476

7.  Life histories of myeloproliferative neoplasms inferred from phylogenies.

Authors:  Nicholas Williams; Joe Lee; Emily Mitchell; Luiza Moore; E Joanna Baxter; James Hewinson; Kevin J Dawson; Andrew Menzies; Anna L Godfrey; Anthony R Green; Peter J Campbell; Jyoti Nangalia
Journal:  Nature       Date:  2022-01-20       Impact factor: 69.504

Review 8.  Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.

Authors:  Karl Haslam; Stephen E Langabeer
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

9.  Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.

Authors:  Niccolò Bartalucci; Laura Calabresi; Manjola Balliu; Serena Martinelli; Maria Caterina Rossi; Jean Luc Villeval; Francesco Annunziato; Paola Guglielmelli; Alessandro M Vannucchi
Journal:  Oncotarget       Date:  2017-05-22

Review 10.  Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.

Authors:  Angela G Fleischman
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.